Ivarmacitinib (ARQ-252)
Ivarmacitinib (ARQ-252) has been filed with a regulator for alopecia areata.
Nothing new since Sep 2023
- Developed by
- Not recorded
- Current phase
- Filed with regulator
- Mechanism
- JAK inhibitor
- Indications
- Alopecia areata
- Also known as
- ARQ252, SHR0302
- Last public activity
- September 2023
- Record confidence
- Medium
Submitted to a regulator and awaiting a decision.
Calms the immune attack on the follicle by blocking JAK signalling - the class that transformed alopecia areata.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Development history
- Phase 2Phase 3
First Phase 3 trial on record: NCT05470413 — Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
ClinicalTrials.gov ↗ - Phase 2
First Phase 2 trial on record: NCT04346316 — A Phase II Study in Patients With Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Reistone Biopharma Company Limited · n=330 · April 2022
A Phase II Study in Patients With Alopecia Areata
Reistone Biopharma Company Limited · n=94 · May 2020
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
Related programmes
Other programmes in the register with the same mechanism: JAK inhibitor.
Cite this page
Hair Pipeline, "Ivarmacitinib (ARQ-252) — development record", hairpipeline.com/pipeline/ivarmacitinib